Renal Cell Carcinoma

FDA Grants Breakthrough Therapy Designation, Orphan Drug Designation to MK-6482
July 29, 2020

The FDA granted breakthrough therapy designation to MK-6482 for the treatment of patients with von Hippel-Lindau disease-associated renal cell carcinoma and orphan drug designation to MK-6482 for von Hippel-Lindau disease.

Scott Tykodi, MD, PhD, on Takeaways from KEYNOTE-427 in Renal Cell Carcinoma
July 24, 2020

The Seattle Cancer Care Alliance expert discusses key takeaways from cohort a of the KEYTRUDA-427 study, evaluating pembrolizumab monotherapy in patients with clear cell renal cell carcinoma.

Scott Tykodi, MD, PhD, Discusses Biomarker Detection, Analysis in RCC
July 13, 2020

The Seattle Cancer Care Alliance Expert offered background on cohort A of the KEYNOTE-427 trial.